266 results
8-K
EX-99.1
BDTX
Black Diamond Therapeutics Inc
9 May 24
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:10am
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Initial Phase 2 data of BDTX-1535 in 2L/3L … , expected to be sufficient to fund operations into Q3 of 2025
CAMBRIDGE, MA, May 9, 2024 (GLOBE NEWSWIRE) – Black Diamond Therapeutics, Inc. (Nasdaq
8-K
77c6z
9 May 24
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:10am
DEFA14A
53xt8wibc7bsvlm10he
24 Apr 24
Additional proxy soliciting materials
4:02pm
PRE 14A
b9ald
12 Apr 24
Preliminary proxy
4:48pm
8-K
890buxgk b40gu
11 Apr 24
Black Diamond Therapeutics Announces Changes to Board of Directors
8:03am
8-K
EX-99.1
zkhwkkw4gz2 zqogskw8
11 Apr 24
Black Diamond Therapeutics Announces Changes to Board of Directors
8:03am
S-8
r4d9yz 8e5p
12 Mar 24
Registration of securities for employees
8:01am
S-8
EX-23.1
msd0zsbea7ctnd
12 Mar 24
Registration of securities for employees
8:01am
S-8
oqaaibz
12 Mar 24
Registration of securities for employees
8:01am
S-8
EX-5.1
rbk84mw
12 Mar 24
Registration of securities for employees
8:01am